Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels — “ABC method”
The current status of screening for gastric cancer-risk (gastritis A, B, C, D) method using combined assay for serum anti-Helicobacter pylori (Hp) IgG antibody and serum pepsinogen (PG) levels, “ABC method”, was reviewed and the latest results of our ongoing trial are reported. It was performed usin...
Gespeichert in:
| Veröffentlicht in: | Proceedings of the Japan Academy, Series B Series B, 2011/07/25, Vol.87(7), pp.405-414 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 414 |
|---|---|
| container_issue | 7 |
| container_start_page | 405 |
| container_title | Proceedings of the Japan Academy, Series B |
| container_volume | 87 |
| creator | MIKI, Kazumasa |
| description | The current status of screening for gastric cancer-risk (gastritis A, B, C, D) method using combined assay for serum anti-Helicobacter pylori (Hp) IgG antibody and serum pepsinogen (PG) levels, “ABC method”, was reviewed and the latest results of our ongoing trial are reported. It was performed using the following strategy: Subjects were classified into 1 of 4 risk groups based on the results of the two serologic tests, anti-Hp IgG antibody titers and the PG I and II levels: Group A [Hp(−)PG(−)], infection-free subjects; Group B [Hp(+)PG(−)], chronic atrophic gastritis (CAG) free or mild; Group C [Hp(+)PG(+)], CAG; Group D [Hp(−)PG(+)]), severe CAG with extensive intestinal metaplasia. Continuous endoscopic follow-up examinations are required to detect early stages of gastric cancer. Asymptomatic Group A, which accounts for 50–80% of all the subjects may be excluded from the secondary endoscopic examination, from the viewpoint of efficiency. Hp-infected subjects should be administered eradication treatment aimed at the prevention of gastric cancer. (Communicated by Takashi SUGIMURA, M.J.A.) |
| doi_str_mv | 10.2183/pjab.87.405 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3171284</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>879102150</sourcerecordid><originalsourceid>FETCH-LOGICAL-c686t-4ab1e4124c11cbb270aba714f79762cd282039a96a86d2af5095107d801673163</originalsourceid><addsrcrecordid>eNqNkT-P1DAQxSME4paDih65o0BZbOePnQZxt4K9k06igdqaOJOsV4kd7OxJ6a6npYQvd58EH7tE0FF4PNL7zdOMXpK8ZHTNmczejnuo11Ksc1o8SlYsy6uUy6p8nKxoJsuUcyrPkmch7CnNeCHZ0-SMMyGL2K-Sb1sIkzeaaLAaPQnaI1pjO1LPRLuhNhYbAiHATFoXdfSHgYCdTHqFvdGuBj3FuXHunTfkutv-FmvXzLFpTvyIYzDWdWhJj7fYB3J_9z2-HxeXGzLgtHPN_d3P58mTFvqAL07_efLl44fPm6v05tP2enNxk-pSllOaQ80wZzzXjOm65oJCDYLlrahEyXXDJadZBVUJsmw4tAWtCkZFIykrRcbK7Dx5d_QdD_WAjUY7eejV6M0AflYOjPpXsWanOnerMiYYl3k0eH0y8O7rAcOkBhM09j1YdIegKiqYpP9DSlExyllBI_nmSGrvQvDYLvswqh5yVg85xwEVc470q79PWNg_wUbg_RHYhwk6XADwk9E9LmbiWKLnIukdeIU2-wWhYr_1</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>879102150</pqid></control><display><type>article</type><title>Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels — “ABC method”</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>MIKI, Kazumasa</creator><creatorcontrib>MIKI, Kazumasa</creatorcontrib><description>The current status of screening for gastric cancer-risk (gastritis A, B, C, D) method using combined assay for serum anti-Helicobacter pylori (Hp) IgG antibody and serum pepsinogen (PG) levels, “ABC method”, was reviewed and the latest results of our ongoing trial are reported. It was performed using the following strategy: Subjects were classified into 1 of 4 risk groups based on the results of the two serologic tests, anti-Hp IgG antibody titers and the PG I and II levels: Group A [Hp(−)PG(−)], infection-free subjects; Group B [Hp(+)PG(−)], chronic atrophic gastritis (CAG) free or mild; Group C [Hp(+)PG(+)], CAG; Group D [Hp(−)PG(+)]), severe CAG with extensive intestinal metaplasia. Continuous endoscopic follow-up examinations are required to detect early stages of gastric cancer. Asymptomatic Group A, which accounts for 50–80% of all the subjects may be excluded from the secondary endoscopic examination, from the viewpoint of efficiency. Hp-infected subjects should be administered eradication treatment aimed at the prevention of gastric cancer. (Communicated by Takashi SUGIMURA, M.J.A.)</description><identifier>ISSN: 0386-2208</identifier><identifier>ISSN: 1349-2896</identifier><identifier>EISSN: 1349-2896</identifier><identifier>DOI: 10.2183/pjab.87.405</identifier><identifier>PMID: 21785258</identifier><language>eng</language><publisher>Japan: The Japan Academy</publisher><subject>anti-Helicobacter pylori (Hp) IgG antibody ; Antibodies, Bacterial - blood ; cancer screening ; Early Detection of Cancer - methods ; gastric cancer ; Helicobacter pylori - immunology ; Humans ; Immunoglobulin G - blood ; pepsinogen (PG) I, II ; Pepsinogen A - blood ; Review ; screening for gastric cancer-risk (gastritis A, B, C, D) method (ABC method) ; serum pepsinogen test method (PG method) ; Stomach Neoplasms - blood ; Stomach Neoplasms - diagnosis ; Stomach Neoplasms - immunology ; Stomach Neoplasms - microbiology</subject><ispartof>Proceedings of the Japan Academy, Series B, 2011/07/25, Vol.87(7), pp.405-414</ispartof><rights>2011 The Japan Academy</rights><rights>2011 The Japan Academy 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c686t-4ab1e4124c11cbb270aba714f79762cd282039a96a86d2af5095107d801673163</citedby><cites>FETCH-LOGICAL-c686t-4ab1e4124c11cbb270aba714f79762cd282039a96a86d2af5095107d801673163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171284/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171284/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,1879,4012,27910,27911,27912,53778,53780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21785258$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MIKI, Kazumasa</creatorcontrib><title>Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels — “ABC method”</title><title>Proceedings of the Japan Academy, Series B</title><addtitle>Proc. Jpn. Acad., Ser. B</addtitle><description>The current status of screening for gastric cancer-risk (gastritis A, B, C, D) method using combined assay for serum anti-Helicobacter pylori (Hp) IgG antibody and serum pepsinogen (PG) levels, “ABC method”, was reviewed and the latest results of our ongoing trial are reported. It was performed using the following strategy: Subjects were classified into 1 of 4 risk groups based on the results of the two serologic tests, anti-Hp IgG antibody titers and the PG I and II levels: Group A [Hp(−)PG(−)], infection-free subjects; Group B [Hp(+)PG(−)], chronic atrophic gastritis (CAG) free or mild; Group C [Hp(+)PG(+)], CAG; Group D [Hp(−)PG(+)]), severe CAG with extensive intestinal metaplasia. Continuous endoscopic follow-up examinations are required to detect early stages of gastric cancer. Asymptomatic Group A, which accounts for 50–80% of all the subjects may be excluded from the secondary endoscopic examination, from the viewpoint of efficiency. Hp-infected subjects should be administered eradication treatment aimed at the prevention of gastric cancer. (Communicated by Takashi SUGIMURA, M.J.A.)</description><subject>anti-Helicobacter pylori (Hp) IgG antibody</subject><subject>Antibodies, Bacterial - blood</subject><subject>cancer screening</subject><subject>Early Detection of Cancer - methods</subject><subject>gastric cancer</subject><subject>Helicobacter pylori - immunology</subject><subject>Humans</subject><subject>Immunoglobulin G - blood</subject><subject>pepsinogen (PG) I, II</subject><subject>Pepsinogen A - blood</subject><subject>Review</subject><subject>screening for gastric cancer-risk (gastritis A, B, C, D) method (ABC method)</subject><subject>serum pepsinogen test method (PG method)</subject><subject>Stomach Neoplasms - blood</subject><subject>Stomach Neoplasms - diagnosis</subject><subject>Stomach Neoplasms - immunology</subject><subject>Stomach Neoplasms - microbiology</subject><issn>0386-2208</issn><issn>1349-2896</issn><issn>1349-2896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkT-P1DAQxSME4paDih65o0BZbOePnQZxt4K9k06igdqaOJOsV4kd7OxJ6a6npYQvd58EH7tE0FF4PNL7zdOMXpK8ZHTNmczejnuo11Ksc1o8SlYsy6uUy6p8nKxoJsuUcyrPkmch7CnNeCHZ0-SMMyGL2K-Sb1sIkzeaaLAaPQnaI1pjO1LPRLuhNhYbAiHATFoXdfSHgYCdTHqFvdGuBj3FuXHunTfkutv-FmvXzLFpTvyIYzDWdWhJj7fYB3J_9z2-HxeXGzLgtHPN_d3P58mTFvqAL07_efLl44fPm6v05tP2enNxk-pSllOaQ80wZzzXjOm65oJCDYLlrahEyXXDJadZBVUJsmw4tAWtCkZFIykrRcbK7Dx5d_QdD_WAjUY7eejV6M0AflYOjPpXsWanOnerMiYYl3k0eH0y8O7rAcOkBhM09j1YdIegKiqYpP9DSlExyllBI_nmSGrvQvDYLvswqh5yVg85xwEVc470q79PWNg_wUbg_RHYhwk6XADwk9E9LmbiWKLnIukdeIU2-wWhYr_1</recordid><startdate>2011</startdate><enddate>2011</enddate><creator>MIKI, Kazumasa</creator><general>The Japan Academy</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QL</scope><scope>C1K</scope><scope>5PM</scope></search><sort><creationdate>2011</creationdate><title>Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels — “ABC method”</title><author>MIKI, Kazumasa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c686t-4ab1e4124c11cbb270aba714f79762cd282039a96a86d2af5095107d801673163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>anti-Helicobacter pylori (Hp) IgG antibody</topic><topic>Antibodies, Bacterial - blood</topic><topic>cancer screening</topic><topic>Early Detection of Cancer - methods</topic><topic>gastric cancer</topic><topic>Helicobacter pylori - immunology</topic><topic>Humans</topic><topic>Immunoglobulin G - blood</topic><topic>pepsinogen (PG) I, II</topic><topic>Pepsinogen A - blood</topic><topic>Review</topic><topic>screening for gastric cancer-risk (gastritis A, B, C, D) method (ABC method)</topic><topic>serum pepsinogen test method (PG method)</topic><topic>Stomach Neoplasms - blood</topic><topic>Stomach Neoplasms - diagnosis</topic><topic>Stomach Neoplasms - immunology</topic><topic>Stomach Neoplasms - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MIKI, Kazumasa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Proceedings of the Japan Academy, Series B</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MIKI, Kazumasa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels — “ABC method”</atitle><jtitle>Proceedings of the Japan Academy, Series B</jtitle><addtitle>Proc. Jpn. Acad., Ser. B</addtitle><date>2011</date><risdate>2011</risdate><volume>87</volume><issue>7</issue><spage>405</spage><epage>414</epage><pages>405-414</pages><issn>0386-2208</issn><issn>1349-2896</issn><eissn>1349-2896</eissn><abstract>The current status of screening for gastric cancer-risk (gastritis A, B, C, D) method using combined assay for serum anti-Helicobacter pylori (Hp) IgG antibody and serum pepsinogen (PG) levels, “ABC method”, was reviewed and the latest results of our ongoing trial are reported. It was performed using the following strategy: Subjects were classified into 1 of 4 risk groups based on the results of the two serologic tests, anti-Hp IgG antibody titers and the PG I and II levels: Group A [Hp(−)PG(−)], infection-free subjects; Group B [Hp(+)PG(−)], chronic atrophic gastritis (CAG) free or mild; Group C [Hp(+)PG(+)], CAG; Group D [Hp(−)PG(+)]), severe CAG with extensive intestinal metaplasia. Continuous endoscopic follow-up examinations are required to detect early stages of gastric cancer. Asymptomatic Group A, which accounts for 50–80% of all the subjects may be excluded from the secondary endoscopic examination, from the viewpoint of efficiency. Hp-infected subjects should be administered eradication treatment aimed at the prevention of gastric cancer. (Communicated by Takashi SUGIMURA, M.J.A.)</abstract><cop>Japan</cop><pub>The Japan Academy</pub><pmid>21785258</pmid><doi>10.2183/pjab.87.405</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0386-2208 |
| ispartof | Proceedings of the Japan Academy, Series B, 2011/07/25, Vol.87(7), pp.405-414 |
| issn | 0386-2208 1349-2896 1349-2896 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3171284 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | anti-Helicobacter pylori (Hp) IgG antibody Antibodies, Bacterial - blood cancer screening Early Detection of Cancer - methods gastric cancer Helicobacter pylori - immunology Humans Immunoglobulin G - blood pepsinogen (PG) I, II Pepsinogen A - blood Review screening for gastric cancer-risk (gastritis A, B, C, D) method (ABC method) serum pepsinogen test method (PG method) Stomach Neoplasms - blood Stomach Neoplasms - diagnosis Stomach Neoplasms - immunology Stomach Neoplasms - microbiology |
| title | Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels — “ABC method” |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T13%3A42%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gastric%20cancer%20screening%20by%20combined%20assay%20for%20serum%20anti-Helicobacter%20pylori%20IgG%20antibody%20and%20serum%20pepsinogen%20levels%20%E2%80%94%20%E2%80%9CABC%20method%E2%80%9D&rft.jtitle=Proceedings%20of%20the%20Japan%20Academy,%20Series%20B&rft.au=MIKI,%20Kazumasa&rft.date=2011&rft.volume=87&rft.issue=7&rft.spage=405&rft.epage=414&rft.pages=405-414&rft.issn=0386-2208&rft.eissn=1349-2896&rft_id=info:doi/10.2183/pjab.87.405&rft_dat=%3Cproquest_pubme%3E879102150%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=879102150&rft_id=info:pmid/21785258&rfr_iscdi=true |